Effective for dates of service on or after April 1, 2022, the medication sourcing requirement for the following oncology supportive care medications will no longer apply for outpatient hospital providers:
| Medication Name | Therapeutic Class | Code |
|---|---|---|
Fulphila® |
Colony-stimulating factor |
Q5108 |
Neulasta® |
Colony-stimulating factor |
J2506 |
NyvepriaTM |
Colony-stimulating factor |
Q5122 |
Udenyca® |
Colony-stimulating factor |
Q5111 |
Ziextenzo® |
Colony-stimulating factor |
Q5120 |
Questions? Please contact your Network Management or Provider Relations teams.